Eagle Pharmaceuticals, Inc. · OTC:EGRX

Eagle Pharmaceuticals — Investor Presentation (June 2023)

16 slides from Eagle Pharmaceuticals's investor presentation, Jun 7, 2023

  1. Slide 1: Company Overview June 2023

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview June 2023

  2. Slide 2: Forward-Looking Statements

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and other securities law. Forward - looking statements are stateme

  3. Slide 3: Strong Financial Position

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 3 Strong Financial Position Eagle Pharmaceuticals Financial Position as it Transforms into a Diversified Pharmaceutical Company To date in Q2 2023, we have seen significant reduced net receivables on cash collection while maintaining steady rev

  4. Slide 4: Key Financial Metrics: reiterating our estimates

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 4 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Eagle Pharmaceuticals Key Financial Metrics: reiterating our estimates 4 Earnings Timeline – Actuals and Estimates 2020 2021 2022 2023E Range 2 Adjusted EBITDA (US$M) 1 $64.7 $28.2 $132.

  5. Slide 5: U.S. Bendamustine Revenue as Share of EGRX Total

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 5 5 U.S. Bendamustine Revenue as Share of EGRX Total 2023 Expectations 21% 16% 15% 8% 19% 20% 57% 68% 79% 84% 85% 92% 81% 80% 43% 32% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2016 2017 2018 2019 2020 2021 2022 2023E Other Revenue Sources US

  6. Slide 6: Further Improving Contribution for Key Products

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 6 Further Improving Contribution for Key Products • BENDEKA ® , BELRAPZO ® & TREAKISYM ® • 10% of profits • $11.5M in 2022 4Q 2022: Expiring Development Partner Royalty on Bendamustine Franchise Profits • Includes elimination of 25% royalty on

  7. Slide 7: Acute care product sales update (BARHEMSYS and BYFAVO)

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 7 Q2 QTD total net product sales currently equal to Q1 2023 revenues with 4 weeks of Q2 sales remaining ‒ Combined net product sales for Q1 2023 were ~$1M (which grew 32% sequentially) ‒ Momentum continues to build with product adoption by key

  8. Slide 8: Acute Care Business Update: Landiolol

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 8 Acute Care Business Update Landiolol On June 1, 2022, AOP Orphan Pharmaceuticals GmbH (“AOP”), with whom the Company entered into a licensing agreement in August 2021, submitted an NDA for landiolol , a short - acting, intravenous, cardio - s

  9. Slide 9: Overview of Eagle's Business Development Strategy

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 9 Overview of Eagle’s Business Development Strategy Value OpEx End Market Size Product Portfolio x Goal for an immediately accretive transaction x Debt ratio of ~2.5x x Leverage infrastructure x Opportunity for synergies / expense reductions x

  10. Slide 10: Eagle Product Portfolio Is Supported by In-Person Commercial Team

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 10 Eagle Product Portfolio Is Supported by 75 - Person Commercial Team RYANODEX ® For treatment of malignant hyperthermia BARHEMSYS ® For prevention of PONV*, and treatment of PONV in patients who received antiemetic prophylaxis with an agent o

  11. Slide 11: Product Candidates and Pipeline Opportunities

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 11 Eagle Pharmaceuticals Product Candidates and Pipeline Opportunities ● Novel first - in - class broad - spectrum anti - virulence agent being developed for the treatment of severe community - acquired bacterial pneumonia ● Global Phase 2 stud

  12. Slide 12: Financial Appendix

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 12 12 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Financial Appendix

  13. Slide 13: Non-GAAP Financial Measures

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 13 Non - GAAP Financial Measures In addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted EBITDA, adj usted non - GAAP earnings per share, adjusted EBITDA multiple, adjusted non - GAAP

  14. Slide 14: © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 14 14 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved.

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 14 14 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved.

  15. Slide 15: © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 15 15 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved.

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 15 15 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved.

  16. Slide 16: Thank You!

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 16 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Thank You!

Eagle Pharmaceuticals — Investor Presentation (June 2023) on 6ix